Home | For Faculty | Help | About | Webmaster

Lbachir BenMohamed

Professor and Director, Cellular and Molecular Immunology, Ophthalmology
School of Medicine

Ph.D., Pasteur Institute, Paris, France, 1997, Immunology and Vaccine Development

Phone: 949-824- 8937
Fax: 949-824-9626
Email: lbenmoha@uci.edu

University of California, Irvine
843 Health Sciences Road
Hewitt Hall , Building 843, 2nd Floor, Room 2032
Mail Code: 4390
Irvine, CA 92697

picture of Lbachir  BenMohamed

Research
Interests
Two major topics: (1) Infection and Immunity/immunopathology; (2) Cancer and immunity/immunopathology
   
URLs BenMohamed Lab
   
Discovery Eye Foundation
   
Academic
Distinctions
• 1992-1996 Assistant Researcher. Immuno-Parasitology, Department of Immunology, Pasteur Institute, France.

• 1997-1998 Research Fellow. Immuno-virology, Department of Hematology/BMT, City of Hope National Medical Center, Duarte, CA, USA

• 1998-1999 Research Fellow. Immuno-virology, Division of Immunology, Beckman Research Institute, City of Hope, Duarte, CA, USA
   
Appointments • 1999-2001 Research Scientist Step I. Immuno-virology, Ophthalmology Research. Cedars-Sinai Medical Center, Los Angeles, CA, USA

• 2002-2004 Assistant Researcher Step IV. Immuno-virology, Department of Ophthalmology & Center for Immunology. University of California Irvine, Orange, CA, USA

• 2004-2007 Assistant Professor of Immunology. Department of Ophthalmology, University of California Irvine, Orange, CA, USA

• 2007-2014 Associate Professor of Immunology, Step I. Department of Ophthalmology, University of California Irvine, Orange, CA, USA

• 2014 -present Professor of Immunology, Step I. Department of Ophthalmology, University of California Irvine, Orange, CA, USA
   
Research
Abstract
Dr. BenMohamed is a Professor of Immunology, the founder and the head of the Laboratory of Cellular and Molecular Immunology in the Department of Ophthalmology at the University of California. He also holds a joint appointment with the Center of Immunology at UC Irvine and with Chao Family Comprehensive Cancer Center UCI Medical center. Dr. BenMohamed received his Ph.D. in Immunology from the Pasteur Institute, Paris, France in 1997 where he worked as the key developer and co-inventor of a new promising vaccine strategy that uses mucosal delivery of clinically approved lipopeptide molecules. Dr. BenMohamed has been involved in clinical immunology, humoral and cellular immune responses, epitope mapping, epitope improvement, and the development and optimization of sub-unit vaccines against several infectious diseases including malaria Plasmodium falciparum, human immunodeficiency virus (HIV), human cytomegalovirus (HCMV) and herpes simplex virus type 1 and type 2 (HSV-1 and HSV-2). Dr. BenMohamed is an independent immunologist, with a national and international reputation in vaccine development against both infectious diseases and cancer. Dr. BenMohamed is well integrated into the scientific community within the United States as well as Europe and is actively involved in a number of professional societies including American Association of Immunologists (AAI), American Society for Microbiology (ASM), American Society for Hematology (ASH), Association for Research in Vision and Ophthalmology (ARVO).
   
Available Technologies
Publications 1. Fidock DA, Gras-Masse H, Lepers JP, Brahimi K, BenMohamed L, Mellouk S, Guerin-Marchand C, Londono A, Raharimalala L & Meis JF. Plasmodium falciparum liver stage antigen-1 is well conserved and contains potent B and T cell determinants. The Journal of Immunology. 1994.153(1): 190-204.

2. Bottius E, BenMohamed L, Brahimi K, Gras H, Lepers JP, Raharimalala L, Aikawa M, Meis J, Slierendregt B, Tartar A, Thomas A & Druilhe P. A novel Plasmodium falciparum sporozoite and liver stage antigen (SALSA) defines major B, T helper, and CTL epitopes. The Journal of Immunology. 1996. 156(8): 2874-84.

3. BenMohamed L, Gras-Masse H, Tartar A, Daubersies P, Brahimi K, Bossus M, Thomas A & Druilhe P. Lipopeptide immunization without adjuvant induces potent and long-lasting B, T helper, and cytotoxic T lymphocyte responses against a malaria liver stage antigen in mice and chimpanzees. European Journal of Immunology. 1997. 27(5): 1242-53.

4. Bossus M, BenMohamed L, Londono A, Barbier B, Tartar A, Druilhe P & Gras-Masse H. Improved detection of human antibodies to a Plasmodium antigen using a peptide modified with Aib residues. Journal of Peptide Science. 1997. 3(1): 47-53.

5. Daubersies P, Thomas AW, Millet P, Brahimi K, Langermans JA, Ollomo B, BenMohamed L, Slierendregt B, Eling W, Van Belkum A, Dubreuil G, Meis JF, Guérin-Marchand C, Cayphas S, Cohen J, Gras-Masse H, Druilhe P. Protection against Plasmodium falciparum malaria in chimpanzees by immunization with the conserved pre-erythrocytic liver-stage antigen 3. Nature Medicine. 2000. 6(11): 1258-63.

6. BenMohamed L, Krishnan R, Longmate J, Auge C, Low L, Primus J, Diamond DJ. Induction of CTL response by a minimal epitope vaccine in HLA A*0201/DR1 transgenic mice: dependence on HLA class II restricted T(H) response. Human Immunology. 2000. 61(8): 764-79.

7. BenMohamed L, Thomas A, Bossus M, Brahimi K, Wubben J, Gras-Masse H, Druilhe P. High immunogenicity in chimpanzees of peptides and lipopeptides derived from four new Plasmodium falciparum pre-erythrocytic molecules. Vaccine. 2000. 18(25): 2843-55.

8. Brahimi K, Badell E, Sauzet JP, BenMohamed L, Daubersies P, Guérin-Marchand C, Snounou G, Druilhe P. Human antibodies against Plasmodium falciparum liver-stage antigen 3 cross-react with Plasmodium yoelii preerythrocytic-stage epitopes and inhibit sporozoite invasion in vitro and in vivo. Infection and Immunity. 2001. 69(6): 3845-52.

9. Perng GC, Maguen B, Jin L, Mott KR, Kurylo J, BenMohamed L, Yukht A, Osorio N, Nesburn AB, Henderson G, Inman M, Jones C, Wechsler SL. A novel herpes simplex virus type 1 transcript (AL- RNA) antisense to the 5? end of the latency-associated transcript produces a protein in infected rabbits. Journal of Virology. 2002. 76(16): 8003-10.

10. BenMohamed L, Wechsler SL, Nesburn AB. Lipopeptide vaccines–yesterday, today, and tomorrow. Lancet Infectious Diseases. 2002. 2(7): 425-31.

11. BenMohamed L, Belkaid Y, Loing E, Brahimi K, Gras-Masse H, Druilhe P. Systemic immune responses induced by mucosal administration of lipopeptides without adjuvant. European Journal of Immunology. 2002. 32(8): 2274-81.

12. BenMohamed L, Krishnan R, Auge C, Primus JF, Diamond DJ. Intranasal administration of a synthetic lipopeptide without adjuvant induces systemic immune responses. Immunology. 2002. 106(1): 113-21.

13. Vichier-Guerre S, Lo-Man R, BenMohamed L, Dériaud E, Kovats S, Leclerc C, Bay S. Induction of carbohydrate-specific antibodies in HLA-DR transgenic mice by a synthetic glycopeptide: a potential anti cancer vaccine for human use. Journal of Peptide Research. 2003. 62(3): 117-24.

14. BenMohamed L, Bertrand G, McNamara CD, Gras-Masse H, Hammer J, Wechsler SL & Nesburn AB. Identification of novel immunodominant CD4+ Th1-type T-cell peptide epitopes from herpes simplex virus glycoprotein D that confer protective immunity. Journal of Virology. 2003. 77(17): 9463- 73.

15. Zhu X, Ramos TV, Gras-Masse H, Kaplan BE & BenMohamed L. Lipopeptide epitopes extended by an Nepsilon-palmitoyl-lysine moiety increase uptake and maturation of dendritic cells through a Toll- like receptor-2 pathway and trigger a Th1-dependent protective immunity. European Journal of Immunology. 2004. 4(11): 3102-14.

16. Lo-Man R, Vichier-Guerre S, Perraut R, Dériaud E, Huteau V, BenMohamed L, Diop OM, Livingston PO, Bay S & Leclerc C. A fully synthetic therapeutic vaccine candidate targeting carcinoma- associated Tn carbohydrate antigen induces tumor-specific antibodies in nonhuman primates. Cancer Research. 2004. 64(14): 4987-94.

17. BenMohamed L, Thomas A & Druilhe P. Long-term multiepitopic cytotoxic-T-lymphocyte responses induced in chimpanzees by combinations of Plasmodium falciparum liver-stage peptides and lipopeptides. Infection and Immunity. 2004. 72(8): 4376-84.

18. Peng W, Henderson G, Inman M, BenMohamed L, Perng GC, Wechsler SL & Jones C. The locus encompassing the latency-associated transcript of herpes simplex virus type 1 interferes with and delays interferon expression in productively infected neuroblastoma cells and trigeminal Ganglia of acutely infected mice. Journal of Virology. 2005. 79(10): 6162-71.

19. Nesburn AB, Ramos TV, Zhu X, Asgarzadeh H, Nguyen V & BenMohamed L. Local and systemic B cell and Th1 responses induced following ocular mucosal delivery of multiple epitopes of herpes simplex virus type 1 glycoprotein D together with cytosine-phosphate-guanine adjuvant. Vaccine. 2005. 23(7): 873-83.

20. Zhang X, Issagholian A, Berg EA, Fishman JB, Nesburn AB & BenMohamed L. Th-cytotoxic T- lymphocyte chimeric epitopes extended by Nepsilon-palmitoyl lysines induce herpes simplex virus type 1-specific effector CD8+ Tc1 responses and protect against ocular infection. Journal of Virology. 2005. 79(24): 15289-301.

21. Bettahi I, Zhang X, Afifi RE & BenMohamed L. Protective immunity to genital herpes simplex virus type 1 and type 2 provided by self-adjuvanting lipopeptides that drive dendritic cell maturation and elicit a polarized Th1 immune response. Viral Immunology. 2006. 19(2): 220-36.

22. Nesburn AB, Bettahi I, Zhang X, Zhu X, Chamberlain W, Afifi RE, Wechsler SL & BenMohamed L. Topical/mucosal delivery of sub-unit vaccines that stimulate the ocular mucosal immune system. Ocular Surface. 2006. 4(4): 178-87.

23. Nesburn AB, Bettahi I, Dasgupta G, Chentoufi AA, Zhang X, You S, Morishige N, Wahlert AJ, Brown DJ, Jester JV, Wechsler SL & BenMohamed L. Functional Foxp3+ CD4+ CD25(Bright+) “natural” regulatory T cells are abundant in rabbit conjunctiva and suppress virus-specific CD4+ and CD8+ effector T cells during ocular herpes infection. Journal of Virology. 2007. 81(14): 7647-61.

24. Carpenter D, Hsiang C, Brown DJ, Jin L, Osorio N, BenMohamed L, Jones C & Wechsler SL. Stable cell lines expressing high levels of the herpes simplex virus type 1 LAT are refractory to caspase 3 activation and DNA laddering following cold shock induced apoptosis. Virology. 2007. 369(1): 12-8.

25. Bettahi I, Nesburn AB, Yoon S, Zhang X, Mohebbi A, Sue V, Vanderberg A, Wechsler SL & BenMohamed L. Protective immunity against ocular herpes infection and disease induced by highly immunogenic self-adjuvanting glycoprotein D lipopeptide vaccines. Investigative Ophthalmology and Visual Science. 2007. 48(10): 4643-53.

26. Carpenter D, Henderson G, Hsiang C, Osorio N, BenMohamed L, Jones C & Wechsler SL. Introducing point mutations into the ATGs of the putative open reading frames of the HSV-1 gene encoding the latency associated transcript (LAT) reduces its anti-apoptosis activity. Microbes and Pathogens. 2008. 44(2):98-102.

27. Chentoufi AA, Zhang X, Lamberth K, Dasgupta G, Bettahi I, Nguyen A, Wu M, Zhu X, Mohebbi A, Buus S, Wechsler SL, Nesburn AB, BenMohamed L. HLA-A*0201-restricted CD8+ cytotoxic T lymphocyte epitopes identified from herpes simplex virus glycoprotein D. The Journal of Immunology. 2008. 180(1): 426-37.

28. Renaudet O, BenMohamed L, Dasgupta G, Bettahi I & Dumy P. Towards a self-adjuvanting multivalent B and T cell epitope containing synthetic glyco-lipopeptide cancer vaccine. Chemistry Enabling Drug Discovery (ChemMedChem). 2008. 3(5): 737-41.

29. Zhang X, Castelli FA, Zhu X, Wu M, Maillère B & BenMohamed L. Gender-Dependent HLA-DR Restricted Epitopes Identified from the Herpes Simplex Virus Type 1 Glycoprotein D. Clinical Vaccine Immunology. 2008. (9): 1436-49.

30. Chentoufi AA, Binder NR; Berka N, Durrand G, Nguyen A, Bettahi I, Maillere B & BenMohamed L. Asymptomatic Human CD4+ Cytotoxic T-Cell Epitopes Identified from Herpes Simplex Virus Glycoprotein B. Journal of Virology. 2008. (23): 11792-802.

31. Bettahi I; Dasgupta G; Renaudet O; Chentoufi AA; Zhang X; Carpenter D; Yoon S; Dumy P & BenMohamed L. Antitumor Activity of a Self-Adjuvanting Glyco-Lipopeptide Vaccine Bearing B-Cell, CD4+ and CD8+ T-Cell Epitopes. Cancer Immunology and Immunotherapy. 2009. 58(2): 187-200.

32. Mott KR, Bresee CJ, Allen SJ, BenMohamed L, Wechsler SL & Ghiasi H. Level of Herpes Simplex Virus Type 1 latency correlates with severity of corneal scarring and exhaustion of CD8+ T cells in trigeminal ganglia of latently infected mice. Journal of Virology. 2009. 83(5): 2246-54.

33. Mott KR, Chentoufi AA, Carpenter D, BenMohamed L, Wechsler SL & Ghiasi H. The role of a glycoprotein K (gK) CD8+ T-cell epitope of herpes simplex virus on virus replication and pathogenicity. Investigative in Ophthalmology and Visual Science. 2009. 50(6): 2903-12.

34. Zhang X, Chentoufi AA, Dasgupta G, Nesburn AB, Wu M, Zhu X, Carpenter D, Wechsler SL, You S, & BenMohamed L. A genital tract peptide epitope vaccine targeting TLR-2 efficiently induces local and systemic CD8(+) T cells and protects against herpes simplex virus type 2 challenge. Mucosal Immunology (Nature Publishing Group). 2009. 2(2): 129-43.

35. Dasgupta G., Chentoufi AA., Wechsler SL., Nesburn AB & BenMohamed L. Herpes Simplex Virus Vaccine Development: Notes and Challenges from a Battlefield. Expert Review Vaccine. 2009. 8(8): 1023-35.

36. Chentoufi AA., Nesburn AB & BenMohamed L. Recent Advances in Multivalent Self-Adjuvanting Glyco-lipopeptide Vaccine Strategies against Breast Cancer. Archivum Immunologiae et Therapiae Experimentalis. 2009. 57(6): 409-23.

37. Chentoufi A.A., Dasgupta G., Azeem A. Choudhury Z., Christensen N, Wechsler SL., Nesburn AB & BenMohamed L. A Novel Human Leukocyte Antigen (HLA-A*0201) Transgenic Rabbit Model to Evaluate the Protective Efficacy of Human CD8+ T-Cell Epitopes against Ocular Herpes Infection and Disease. Journal of Immunology. 2010. 184(5): 2561-71.

38. Dasgupta G, Nesburn AB, Wechsler SL. & BenMohamed L. Developing an asymptomatic mucosal herpes vaccine: the present and the future. Future Microbiology. 2010. 5:1-4.

39. Chentoufi AA, Dasgupta G, Nesburn AB, Bettahi I, Binder NR, Choudhury ZS, Chamberlain WD, Wechsler SL, & BenMohamed L. Nasolacrimal duct closure modulates ocular mucosal and systemic CD4(+) T-cell responses induced following topical ocular or intranasal immunization. Clinical Vaccine Immunology. 2010. 17(3): 342-53.

40. Renaudet O, Dasgupta G, Bettahi I, Shi A, Nesburn AB, Dumy P & BenMohamed L. Linear and branched glyco-lipopeptide vaccines follow distinct cross-presentation pathways and generate different magnitudes of antitumor immunity. PLoS One. 2010. 5(6): 11216.

41. Chentoufi AA, & BenMohamed L. Future Viral Vectors for the Delivery of Asymptomatic Herpes Epitopes-Based Immunotherapeutic Vaccines. Future Virology. 2010. 5(5): 525-528.

42. Dasgupta G, Chentoufi AA, You S, Falatoonzadeh P, Urbano LA, Akhtarmalik A, Nguyen K, Ablabutyan L, Nesburn AB & BenMohamed L. Engagement of TLR2 Reverses the Suppressor Function of Conjunctiva CD4+CD25+ Regulatory T Cells, and Promotes Herpes Simplex Virus Epitope-Specific CD4+CD25- Effector T Cell Responses. Investigative in Ophthalmology and Visual Sciences. 2011. 52(6): 3321-33.

43. Jiang, X. Chentoufi AA., Hsiang, C., Carpenter, D., Osorio, N., BenMohamed L. Fraser, NW., Jones, C., & Wechsler SL. The herpes simplex virus type 1 latency associated transcript (LAT) can protect neuronal derived C1300 and Neuro2A cells from Granzyme B induced apoptosis and CD8+ T-cell killing. Journal of Virology. 2011. 85(5): 2325-32.

44. Perlaza BL., Sauzet JP. Brahimi K. BenMohamed L & Druilhe P. Interferon-?, a valuable surrogate marker of protective immunity against P. falciparum pre-erythrocytic stages. Malaria Journal. 10(1): 27. 2011.

45. Allen SJ, Hamrah P, Gate D, Mott KR, Mantopoulos D, Zheng L, Town T, Jones C, von Andrian UH, Freeman GJ, Sharpe AH, BenMohamed L, Ahmed R, Wechsler SL & Ghiasi H. The role of LAT in increased CD8+ T cell exhaustion in trigeminal ganglia of mice latently infected with herpes simplex virus 1. Journal of Virology. 2011. 85(9): 4184-97.

46. Dasgupta G. & BenMohamed L. Of Mice and Not Humans: Reliable Pre-clinical Animal Models for Evaluation of Human Herpes Immunotherapeutic Vaccine Candidates? Vaccine. 2011. 29(35): 5824- 36.

47. Rubbo PA, Tuaillon E, Nagot N, Chentoufi AA, Bollore K, Reynes J, Vendrell JP, BenMohamed L & DE Perre PV. HIV-1 Infection Impairs HSV-Specific CD4+ and CD8+ T Cell Response by Reducing Th1 Cytokines and CCR5 Ligand Secretion. Journal of Acquired Immune Deficiency Syndrome. 2011. 58(1):9-17.

48. Allen SJ, Mott KR, Chentoufi AA, BenMohamed L, Wechsler SL, Ballantyne CM & Ghiasi H. CD11c controls the capacity of HSV-1 responses to limit virus replication during primary infection. Journal of Virology. 2011. 85(19):9945-55.

49. Chentoufi, A.A., E. Kritzer, M. Tran, G. Dasgupta, R. EA., J. Xianzhi, D. Carpenter, O. Osorio, A. B. Nesburn, S. L. Wechsler & L. BenMohamed. The Herpes Simplex Virus-1 Encoded Latency- Associated Transcript Promotes Dysfunctional Virus-Specific CD8+ T Cells in Latently Infected Trigeminal Ganglia: A Novel Immune Evasion Mechanism. Journal of Virology. 2011. 85(17): 9127- 38.

50. Chentoufi AA., Dasgupta G., Huw D., Falatoonzadeh P., Lim CH., Kalantari-Dehaghi M., Felgner LP. & BenMohamed L. Identification of Asymptomatic Antigens by Probing Whole Herpes Simplex Virus Type 1 and Type 2 Open Reading Frame Proteome Microarrays By Sera From Seropositive Asymptomatic Versus Symptomatic Individuals. Journal of Virology. 2012. In press.

51. Immunodominant "asymptomatic" herpes simplex virus 1 and 2 protein antigens identified by probing whole-ORFome microarrays with serum antibodies from seropositive asymptomatic versus symptomatic individuals. Chentoufi AA., Dasgupta G., Huw D., Falatoonzadeh P., Lim CH., Kalantari-Dehaghi M., Felgner LP. & BenMohamed L. Journal of Virology. 2012. (8): 4358-69.

52. Discovery of potential diagnostic and vaccine antigens in herpes simplex virus 1 and 2 by proteome-wide antibody profiling. Kalantari-Dehaghi, M., Chun S., Chentoufi AA., Molina, DM., Liang L., Dasgupta G., Ms. Pablo G., Jasinskas A., Nakajima-Sasaki R., BenMohamed L., Felgner, LP. & Huw DM.,. Journal of Virology. 2012. (8): 4328-39.

53. Towards a rational design of an asymptomatic clinical herpes vaccine: the old, the new, and the unknown. Chentoufi, AA., Kritzer, E. & BenMohamed L. Clinical & Developmental Immunology. 2012. 187585.

54. Future of an “Asymptomatic” T-cell Epitope-Based Therapeutic Herpes Simplex Vaccine. Dervillez, X., Gottimukkala, C., Kabbara, KW. Nguyen, C., Kim, SM., Nesburn, A.B., Wechsler S.L. & BenMohamed L. Future Virology. 2012. 7(4): 371-378.

55. The Herpes Simplex Virus Type 1 Latency Associated Transcript Inhibits Phenotypic and Functional Maturation of Dendritic Cells. Chentoufi, AA.,Dervillez, X., Dasgupta G., Nguyen C., Kabbara, KW., Jiang X., Nesburn, A.B., Wechsler S.L. & BenMohamed L. Viral Immunology. 2012. (3):204-15.

56. Targeting the Genital Tract Mucosa with a Lipopeptide/Recombinant Adenovirus Prime/Boost Vaccine Induces Potent and Long-Lasting CD8+ T Cell Immunity Against Herpes: Importance of Myeloid Differentiation Factor 88. Xiuli Zhang; Xavier Dervillez; Aziz Alami Chentoufi; Tina Badakhshan; Ilham Bettahi & BenMohamed L. The Journal of Immunology. 2012. 89(9): 4496-509.

57. Mucosal Herpes Immunity and Immuno-pathology to Ocular, Oro-Facial and Genital Herpes Simplex Virus Infections. Chentoufi, A. A. & BenMohamed L. Clinical and Developmental Immunology. 2012. In press.

58. Immunity to Ocular and Genital Herpes Simplex Viruses Infections. Chentoufi, A. A.; BenMohamed L., Philippe Van De Perre, and Ali A. Ashkar. Clinical and Developmental Immunology. 2012. In press.

59. Current Trends in Negative Immuno-Synergy between Two Sexually Transmitted Infectious Viruses: HIV-1 and HSV-1/2. Aziz Alami Chentoufi; Xiuli Zhang; Pierre Alan Rubbo; Xavier Dervillez; Nicolas Nagot, Edouard Tuaillon; Philippe Van De Perre & BenMohamed L. Current Trends in Immunology. 2012. 13:51-68.

60. Boosting Immunity to Small Tumor-Associated Carbohydrates with Bacteriophage Q? Capsids. Yin Z, Comellas-Aragones M, Chowdhury S, Bentley P, Kaczanowska K, BenMohamed L, Gildersleeve JC, Finn MG, Huang X. ACS Chem Biol. 2013 Mar 29. In Press.

61. Valosin Containing Protein Disease is Associated with Cytokine Imbalances E. Dec, P. Rana, V. Katheria, R. Dec, M. Khare, A. Nalbandian, S-Y Leu, S. Radom-Aizik, F. Zaldivar, BenMohamed L., V. Kimonis. 2013. Clinical and Translational Science. In Press.

62. HLA-A*01:03, -A*24:02, -B*08:01, -B*27:05, -B*35:01, -B*44:02 and C*07:01 Monochain Transgenic / H-2 Class I Null Mice: Novel Versatile Pre-Clinical Models of Human T Cell Responses. R. Boucherma, H. Kridane-Miledi, R. Bouziat, M. Rasmussen†, T. Gatard, F. Langa-Vives, B. Lemercier, A. Lim, M. Bérard, BenMohamed L., S. Buus, R. Rooke, and F. A. Lemonnier. 2013. The Journal of Immunology. In Press.
   
Grant CURRENT RESEARCH GRANTS 1. RO1 Grant from National Institute of Health (NEI). Ocular Mucosal Immunity Induced By HSV1 Lipopeptides. EY14900. September, 30, 2003 to May 31 2012. Principal Investigator: Lbachir BenMohamed. 2. Discovery Eye Foundation. Therapeutic vaccine against ocular herpes in HLA transgenic rabbits.. January, 1, 2009 to December 31 2015. Principal Investigator: Lbachir BenMohamed. 3. RO1 Grant from National Institute of Health (NEI). Role of TGFbeta in Corneal Stromal Wound Healing. EY007348 March, 1st, 2006 to April 31 2011. Co-Investigator (10%): Lbachir BenMohamed. 4. RO1 Grant from National Institute of Health (NEI). Corneal HSV-1: Immunopathologic Mechanisms of HSK. EY018171. January, 1st, 2008 to December 31 2010. Co-Investigator (10%): Lbachir BenMohamed. 5. R24 Core grant from National Institute of Health (NEI). Vision Research Infrastructure Development. EY016663. June 1, 2005-May 31, 2010. Co-Investigator, Director of Cell Culture Module (5%): Lbachir BenMohamed. 6. T32 Grant from National Institute of Health (NIAID). AI060573 Immunology Research Training Program. In collaboration with faculty members at the New Center for Immunology at UCI. June 1, 2005-May 31, 2010 Co-Investigator: Lbachir BenMohamed. COMPLETED RESEARCH GRANTS 1. RO3 Grant from National Institute of Health (NEI). Interaction of HSV-1 LAT gene with dendritic cell function. EY14017, April 1, 2002 to March 31 2005. Principal Investigator: Lbachir BenMohamed. 2. Career Development Award, RPB Grant Research To Prevent Blindness. Therapeutic Efficacy of Lipopeptide vaccines against ocular herpes in rabbits. 445043-53779. September, 30, 2005 to August 31 2006. Principal Investigator: Lbachir BenMohamed. 3. RO1 Grant from National Institute of Health (NEI). Ocular Mucosal Immunity. EY015225. August, 1st, 2004 to June 31 2008. Co-Principal Investigator (20%): Lbachir BenMohamed. RESEARCH GRANT PROPOSALS SUBMITTED PENDING REVIEW 1. (BenMohamed) 12/01/09 – 11/30/11 NIH/NCI Towards Multivalent Anti-Prostate Cancer Nano-Vaccine 2. (BenMohamed) 12/01/09 – 11/30/14 NIH/NEI Therapeutic Ocular HSV Vaccine in HLA Transgenic Rabbits 3. (BenMohamed) 12/01/09 – 11/30/14 NIH/NEI “Ocular Mucosal Immunity Induced by HSV-1 Lipopeptide” 4. NIH/NCI SUB-CONTRACT with University of Michigan (PI. Dr. Huang) 5. (BenMohamed) 12/01/09 – 11/30/14 NIH Misc Agencies & Depts “Human CD8+ T cells and recurrent ocular herpes disease” 6. (BenMohamed) 01/01/10 – 12/31/10 The Discovery Eye Foundation “Towards the rational design of a therapeutic vaccine to prevent Ocular Herpes” 7. (BenMohamed) 01/01/10 – 12/31/10 Bill & Melinda Gates Foundation ”G
   
Professional
Societies
American Association of Immunologists (AAI)
Association for Research in Vision and Ophthalmology (ARVO)
American Society for Microbiology (ASM)
American Association for Cancer Research (AACR)
   
Other Experience Founder
Micro Antigens Technologies, LLC 2007—Pres

Graduate Programs Immunology and Pathogenesis

   
   
Link to this profile http://www.faculty.uci.edu/profile.cfm?faculty_id=5696
   
Last updated 12/15/2014